CANNABIS-BASED medicinal products, such as Sativex, could soon be available to sufferers of Multiple Sclerosis (MS) and other medical conditions on prescription.
This follows confirmation by the Minister for State at the Department of Health, Róisín Shortall, that the department “is examining the issues associated with applying controls, similar to those that apply to other controlled drugs that can be misused, such as morphine and methadone, to cannabis-based medicinal products to permit them to be prescribed and dispensed in Ireland.”
In a written response to a Dáil question tabled by Luke Flanagan, Ms Shortall said: “I am aware that claims have been made in respect of the possible health benefits of cannabis-based medicinal products for patients suffering from certain conditions such as MS.
“I am also aware that Sativex [manufactured by UK-based pharma company, GW Pharmaceuticals] is authorised in the UK for the relief of spasm in patients with MS,” Ms Shortall added.
Mr Flanagan described the current Government policy of prohibiting the supply of cannabis-based medicinal products as “heartless and cruel”.
He said Ms Shortall’s response “gives room for hope” to sufferers of conditions such as MS.
“I received a letter from one person who purchased Sativex in the North. The Sativex dealt with the person’s incontinence and the patient didn’t have to use a nappy while on the medication, but is now back wearing a nappy because this person can’t buy Sativex in the Republic,” he said.
The chairman of the Irish Patients’ Association, Stephen McMahon, last night welcomed the Minister’s statement that the Government is considering allowing Sativex to be prescribed.
